Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01089127 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 552
- Enrollment target
NCT01089127 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 552 participants.
The verdict
NCT01089127, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 552 participants
- Enrollment target
Study Summary
This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol.
Interventions
- DRUG Placebo to indacaterol
- DRUG Salmeterol 50 μg
- DRUG Placebo to salmeterol
- DRUG Indacaterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 552 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01089127
The ClinicalTrials.gov registry entry for NCT01089127 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 552 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo to indacaterol is the first listed.
NCT01089127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01089127 about?
NCT01089127 is a clinical study titled "Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)". This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol.
What is the current status of trial NCT01089127?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 552 participants. The study started on 2010-03. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01089127?
The interventions under investigation include: Placebo to indacaterol (DRUG), Salmeterol 50 μg (DRUG), Placebo to salmeterol (DRUG), Indacaterol (DRUG).
Who is sponsoring clinical trial NCT01089127?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.